Oncogenex surprises market with $47M secondary offering
This article was originally published in Scrip
Executive Summary
OncoGenex Pharmaceuticals saw its stock price drop more than 20 percent on 16 March when it announced it would sell 4.2 million shares in a common stock offering priced at $12 per share. The stock drop may represent surprise at the news of the offering, since the company had told stockholders at the release of its latest quarterly results on 8 March 2012 that it had enough money to support its operations into 2014.
You may also be interested in...
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.
Roche/Chugai’s Enspryng Not Good Enough In Phase III Myasthenia Gravis Study
Many companies have late-stage myasthenia gravis programs in Phase III, but argenx and its Vyvgart competitors won a reprieve with the failure of IL-6 inhibitor Enspryng (satralizumab).